Prostatic Urethral Lift: Two-year Results After Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia - 06/08/12

Doi : 10.1016/j.urology.2011.10.021

Peter T. Chin ^a, Damien M. Bolton ^b, Greg Jack ^b, Prem Rashid ^c, Jeffrey Thavaseelan ^d, R. James Yu ^e, Claus G. Roehrborn ^f, Henry H. Woo ^g,^⁎
^a Illawarra Private Hospital, Wollongong, New South Wales, Australia
^b Austin Hospital, Melbourne, Victoria, Australia
^c Urology Centre, Port Macquarie, New South Wales, Australia
^d St. John of God Medical Centre, Murdoch, Perth, Western Australia, Australia
^e Stanford University School of Medicine, Stanford, California
^f University of Texas Southwestern Medical Center, Dallas, Texas
^g University of Sydney, Sydney, New South Wales, Australia

Reprint requests: Henry H. Woo, M.D., Sydney Adventist Hospital Clinical School, University of Sydney, P.O. Box 5017, Wahroonga, New South Wales 2076 Australia

Résumé

Objective

To evaluate the effectiveness of the prostatic urethral lift in relieving lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia.

Methods

A total of 64 men, aged ≥55 years, with moderate to severe symptomatic benign prostatic hyperplasia were treated and followed up at 6 Australian institutions. The treatment consisted of transurethral delivery of small implants to secure the prostatic lobes in an open condition, thereby reducing obstruction of the urethral lumen. The effectiveness, including International Prostate Symptom Score, quality of life, benign prostatic hyperplasia Impact Index, and peak urethral flow rate were assessed at 2 weeks and 3, 6, 12, and 24 months. The effect of this treatment on erectile and ejaculatory function was assessed using the Sexual Health Inventory for Men and Male Sexual Health Questionnaire for Ejaculatory Dysfunction.

Results

The prostatic urethral lift improved LUTS symptoms rapidly and durably. The International Prostate Symptom Score was reduced 42% at 2 weeks, 49% at 6 months, and 42% at 2 years in evaluable patients. The peak flow rate improved by ≥30% (2.4 mL/s) at all intervals compared with baseline. No compromise in sexual function was observed after this treatment.

Conclusion

The present study demonstrated that LUTS and flow improvements without compromising sexual function. Although this was an early study with a small cohort, this therapy shows promise as a new option for patients with LUTS.

Le texte complet de cet article est disponible en PDF.

Plan

Material and Methods

Study protocol

Prostatic urethral lift procedure

	Funding Support: This study was funded by NeoTract, Inc.
	Financial Disclosure: H. Woo, P. Chin, and C. Roehrborn are consultants and clinical trial participants for Neotract, Inc. P. Rashid, D. Bolton, G. Jack, and J. Thavaseelan are clinical trial participants for Neotract, Inc., and J. Yu is a consultant to Neotract, Inc.